Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 7
1984 9
1985 30
1986 61
1987 53
1988 53
1989 74
1990 48
1991 68
1992 71
1993 53
1994 37
1995 49
1996 57
1997 59
1998 61
1999 65
2000 73
2001 58
2002 57
2003 58
2004 62
2005 68
2006 74
2007 76
2008 55
2009 62
2010 65
2011 70
2012 77
2013 71
2014 78
2015 73
2016 72
2017 66
2018 83
2019 83
2020 95
2021 101
2022 105
2023 87
2024 26

Text availability

Article attribute

Article type

Publication date

Search Results

2,470 results

Results by year

Filters applied: . Clear all
Page 1
Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock.
Mathew R, Di Santo P, Jung RG, Marbach JA, Hutson J, Simard T, Ramirez FD, Harnett DT, Merdad A, Almufleh A, Weng W, Abdel-Razek O, Fernando SM, Kyeremanteng K, Bernick J, Wells GA, Chan V, Froeschl M, Labinaz M, Le May MR, Russo JJ, Hibbert B. Mathew R, et al. N Engl J Med. 2021 Aug 5;385(6):516-525. doi: 10.1056/NEJMoa2026845. N Engl J Med. 2021. PMID: 34347952 Clinical Trial.
The treatment groups did not differ significantly with respect to the primary outcome; a primary outcome event occurred in 47 participants (49%) in the milrinone group and in 52 participants (54%) in the dobutamine group (relative risk, 0.90; 95% confidence interval [CI], …
The treatment groups did not differ significantly with respect to the primary outcome; a primary outcome event occurred in 47 participants ( …
Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit.
Jentzer JC, Coons JC, Link CB, Schmidhofer M. Jentzer JC, et al. J Cardiovasc Pharmacol Ther. 2015 May;20(3):249-60. doi: 10.1177/1074248414559838. Epub 2014 Nov 28. J Cardiovasc Pharmacol Ther. 2015. PMID: 25432872 Review.
Each of these medications acts as vasopressors to increase mean arterial pressure by augmenting vascular tone. Inotropes include inodilators (dobutamine and milrinone) and the aforementioned inoconstrictors. These medications act as inotropes by enhancing cardiac output th …
Each of these medications acts as vasopressors to increase mean arterial pressure by augmenting vascular tone. Inotropes include inodilators …
Meta-analysis Comparing the Efficacy of Dobutamine Versus Milrinone in Acute Decompensated Heart Failure and Cardiogenic Shock.
Biswas S, Malik AH, Bandyopadhyay D, Gupta R, Goel A, Briasoulis A, Fonarow GC, Lanier GM, Naidu SS. Biswas S, et al. Curr Probl Cardiol. 2023 Aug;48(8):101245. doi: 10.1016/j.cpcardiol.2022.101245. Epub 2022 May 8. Curr Probl Cardiol. 2023. PMID: 35545181 Review.
This study aims to evaluate the difference between dobutamine and milrinone in patients presenting with acute decompensated heart failure (AHF). ...The cumulative data comparing milrinone with dobutamine indicate an overall marginal benefit of milrinone compa …
This study aims to evaluate the difference between dobutamine and milrinone in patients presenting with acute decompensated heart fai …
Levosimendan or Milrinone for Ventricular Septal Defect Repair With Pulmonary Arterial Hypertension.
Nag P, Chowdhury SR, Behera SK, Das M, Narayan P. Nag P, et al. J Cardiothorac Vasc Anesth. 2023 Jun;37(6):972-979. doi: 10.1053/j.jvca.2023.01.032. Epub 2023 Feb 6. J Cardiothorac Vasc Anesth. 2023. PMID: 36906394 Clinical Trial.
In the present study, the authors sought to compare the role of levosimendan and milrinone in the prevention of low-cardiac-output syndrome in the early postoperative period. ...CONCLUSIONS: In patients undergoing surgical repair for VSD with PAH, levosimendan does not con …
In the present study, the authors sought to compare the role of levosimendan and milrinone in the prevention of low-cardiac-output sy …
Milrinone Dosing and a Culture of Caution in Clinical Practice.
Chong LYZ, Satya K, Kim B, Berkowitz R. Chong LYZ, et al. Cardiol Rev. 2018 Jan/Feb;26(1):35-42. doi: 10.1097/CRD.0000000000000165. Cardiol Rev. 2018. PMID: 29045285 Review.
Milrinone is an invaluable agent in the treatment of end-stage heart failure patients who are refractory to optimal medical therapy. ...Despite these concerns, studies that comprehensively reconcile the dose-response relationship and adverse events are scarce, and no clear …
Milrinone is an invaluable agent in the treatment of end-stage heart failure patients who are refractory to optimal medical therapy. …
Improved mortality and haemodynamics with milrinone in cardiogenic shock due to acute decompensated heart failure.
Rodenas-Alesina E, Luis Scolari F, Wang VN, Brahmbhatt DH, Mihajlovic V, Fung NL, Otsuki M, Billia F, Overgaard CB, Luk A. Rodenas-Alesina E, et al. ESC Heart Fail. 2023 Aug;10(4):2577-2587. doi: 10.1002/ehf2.14379. Epub 2023 Jun 15. ESC Heart Fail. 2023. PMID: 37322827 Free PMC article.
A total of 573 patients were included, of which 366 (63.9%) received milrinone and 207 (36.1%) received dobutamine. Patients receiving milrinone were younger, had better kidney function, and lower lactate at admission. ...Milrinone use was associated with a l …
A total of 573 patients were included, of which 366 (63.9%) received milrinone and 207 (36.1%) received dobutamine. Patients receivin …
Nebulized Milrinone: Choosing Next Steps Wisely.
Ilonze OJ, Pang PS. Ilonze OJ, et al. J Card Fail. 2024 Feb;30(2):337-339. doi: 10.1016/j.cardfail.2023.10.480. Epub 2023 Nov 11. J Card Fail. 2024. PMID: 37952643 No abstract available.
Patient-, Clinician-, and Institution-level Variation in Inotrope Use for Cardiac Surgery: A Multicenter Observational Analysis.
Mathis MR, Janda AM, Kheterpal S, Schonberger RB, Pagani FD, Engoren MC, Mentz GB, Shook DC, Muehlschlegel JD; Multicenter Perioperative Outcomes Group. Mathis MR, et al. Anesthesiology. 2023 Aug 1;139(2):122-141. doi: 10.1097/ALN.0000000000004593. Anesthesiology. 2023. PMID: 37094103 Free article.
The primary outcome was an inotrope infusion (epinephrine, dobutamine, milrinone, dopamine) administered for greater than 60 consecutive min intraoperatively or ongoing upon transport from the operating room. ...RESULTS: Among 51,085 cases across 611 attending anesthesiolo …
The primary outcome was an inotrope infusion (epinephrine, dobutamine, milrinone, dopamine) administered for greater than 60 consecut …
Another Outcome Lost to the Benefits of Levosimendan?
Alexander PMA, Akcan-Arikan A, Shekerdemian LS. Alexander PMA, et al. Pediatr Crit Care Med. 2019 Oct;20(10):992-994. doi: 10.1097/PCC.0000000000002019. Pediatr Crit Care Med. 2019. PMID: 31580276 No abstract available.
Editorial.
Mulholland J. Mulholland J. Perfusion. 2012 Jan;27(1):5-6. doi: 10.1177/0267659111433098. Perfusion. 2012. PMID: 22246229 No abstract available.
2,470 results